Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT06514118
- Locations
- 🇨🇳
Qingdao Central Hospital, Qingdao, Shandong, China
Nutrition Impact on Immunotherapy of Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06500234
- Locations
- 🇨🇳
Qingdao Central Hospital, Qingdao, Shandong, China
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT06138028
- Locations
- 🇨🇳
Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China
🇨🇳Qingdao Central Hospital, Qingdao, Shandong, China
Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05392257
- Locations
- 🇨🇳
Qingdao central Hospital, Qingdao, Shandong, China
Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05267288
- Locations
- 🇨🇳
Qingdao Central Hospital, Qingdao, China
Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 117
- Registration Number
- NCT05267366
- Locations
- 🇨🇳
Qingdao central Hospital, Qingdao, Shandong, China
Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05218629
- Locations
- 🇨🇳
Qingdao central Hospital, Qingdao, Shandong, China
Colchicine Use for Primary Prevention of Coronary Artery Disease
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 6792
- Registration Number
- NCT05175274
- Locations
- 🇨🇳
Mengmei Li, Qingdao, Shandong, China
Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05104281
- Locations
- 🇨🇳
Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China
Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction
Phase 4
- Conditions
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05060588
- Locations
- 🇨🇳
Mengmei Li, Qingdao, Shandong, China
© Copyright 2024. All Rights Reserved by MedPath